{"id":59418,"date":"2026-03-13T21:54:09","date_gmt":"2026-03-13T13:54:09","guid":{"rendered":"https:\/\/flcube.com\/?p=59418"},"modified":"2026-03-13T21:54:10","modified_gmt":"2026-03-13T13:54:10","slug":"sino-biopharms-tqb3454-hits-phase-iii-endpoints-in-idh1-biliary-tract-cancer-chinas-first-idh1-inhibitor-poised-for-nda-filing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59418","title":{"rendered":"Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer \u2013 China’s First IDH1 Inhibitor Poised for NDA Filing"},"content":{"rendered":"\n

Sino Biopharmaceutical<\/strong> (HKG: 1177<\/a>) announced that TQB3454 Tablets<\/strong>, a Category 1 innovative drug<\/strong> developed by subsidiary Chia Tai Tianqing (CTTQ)<\/strong>, achieved pre-defined superiority margins<\/strong> on both Progression-Free Survival (PFS)<\/strong> and Overall Survival (OS)<\/strong> in a pre-specified interim analysis<\/strong> of its Phase III study<\/strong> in advanced biliary tract cancer (BTC) with IDH1 mutations<\/strong>. The Independent Data Monitoring Committee (IDMC)<\/strong> recommended proceeding, and CTTQ has received CDE written consent<\/strong> to submit the NDA<\/strong>, positioning TQB3454 as the world’s second and China’s first<\/strong> IDH1 inhibitor to demonstrate Phase III success in this indication.<\/p>\n\n\n\n

Phase III Interim Analysis Results<\/h2>\n\n\n\n
Endpoint<\/th>Result<\/th>Significance<\/th><\/tr><\/thead>
Progression-Free Survival (PFS)<\/strong><\/td>Met pre-defined superiority margin<\/td>Primary endpoint achievement<\/td><\/tr>
Overall Survival (OS)<\/strong><\/td>Met pre-defined superiority margin<\/td>Primary endpoint achievement<\/td><\/tr>
IDMC Recommendation<\/strong><\/td>Continue study \/ Proceed to NDA<\/td>Independent validation of efficacy<\/td><\/tr>
Regulatory Status<\/strong><\/td>CDE written consent received<\/td>NDA submission imminent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Study Population:<\/strong> Advanced biliary tract cancer patients with IDH1 mutations<\/strong><\/p>\n\n\n\n

Product Profile<\/h2>\n\n\n\n
Attribute<\/th>TQB3454 Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Selective IDH1 mutant enzyme inhibitor<\/strong><\/td><\/tr>
Developer<\/strong><\/td>Chia Tai Tianqing (CTTQ), Sino Biopharm subsidiary<\/td><\/tr>
Drug Class<\/strong><\/td>Category 1 innovative drug (China)<\/td><\/tr>
Target Population<\/strong><\/td>IDH1-mutant advanced biliary tract cancer<\/td><\/tr>
Global Positioning<\/strong><\/td>World’s second<\/strong> IDH1 inhibitor with Phase III BTC success; China’s first<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Impact<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
BTC Incidence<\/strong><\/td>~180,000 new cases annually<\/strong> in China; 15\u201320% harbor IDH1 mutations<\/strong> (~27,000\u201336,000 addressable patients)<\/td><\/tr>
Unmet Need<\/strong><\/td>No approved targeted therapies for IDH1-mutant BTC in China; standard of care (gemcitabine\/cisplatin) offers limited survival benefit<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Ivosidenib (Servier) first global approval in BTC; TQB3454 positions as domestic alternative<\/strong> with potential cost advantage<\/td><\/tr>
Precision Oncology Trend<\/strong><\/td>Validates CTTQ’s molecularly targeted strategy; builds IDH1 franchise for potential expansion to acute myeloid leukemia (AML)<\/td><\/tr>
Revenue Potential<\/strong><\/td>Peak sales RMB 800 million\u20131.2 billion<\/strong> annually in China assuming NRDL inclusion and competitive pricing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n